ArticlesA population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial
Introduction
The use of antenatal corticosteroids for pregnant women at high risk of preterm delivery is among the most effective hospital-based interventions to reduce neonatal mortality associated with preterm birth, a leading cause of childhood mortality.1, 2, 3, 4, 5, 6 A systematic review3 of 21 randomised controlled trials of antenatal corticosteroids showed a 31% relative reduction in neonatal mortality (relative risk [RR] 0·69, 95% CI 0·58–0·81) and an even larger reduction in severe neonatal morbidity. However, a non-significant increased risk of puerperal sepsis (1·35, 0·93–1·95) was noted from eight studies.3 All of the trials were done in hospitals with neonatal intensive care and respiratory support. Similar reductions in neonatal mortality were seen in trials in both high-income countries and middle-income countries (Brazil, Jordan, South Africa, and Tunisia).3
On the basis of this strong evidence, the use of antenatal corticosteroids in hospitals for women at high risk of preterm birth is widely recommended by national and international health organisations.1, 6 Antenatal corticosteroids have been included in the UN list of life-saving commodities for women and children,7 and WHO has recommended dexamethasone for women at risk of preterm birth.7, 8
Whereas 80% of the women at high risk of preterm birth in high-income countries currently receive antenatal corticosteroids, less than 10% of women at risk in low-income countries receive the treatment, and proportions in middle-income countries range from 30% to 50%.6, 9, 10, 11, 12 An important determinant is that less than half of births in low-income countries occur in hospitals with antenatal corticosteroids available.13, 14 Although institutional delivery is increasing, access to tertiary care similar to that in hospitals in middle-income or high-income countries is poor for most women in low-income countries. Thus, to increase coverage of antenatal corticosteroids for women at risk in low-income countries, they would need to be made available in primary care facilities or through community strategies. So far, evidence for the reduction of neonatal mortality from antenatal corticosteroids comes solely from clinical trials done in hospitals with neonatal intensive care. Whether similar reductions would occur in settings, such as primary health-care clinics, in which intensive care for preterm infants might not be available and in which risk of preterm birth might be less accurately assessed, is unclear. Questions have also been raised about risks of infectious morbidity for women and their infants delivered in community settings related to the use of antenatal corticosteroids.15, 16
Many barriers limit effective coverage of antenatal corticosteroids in low-income countries. Estimation of gestational age can be suboptimum in these settings because of low availability of ultrasound, frequent uncertainty about the date of last menstrual period, and inadequate training in the assessment of gestational age.15, 16, 17, 18 Birth attendants in low-resource settings might not have the skills necessary to assess risk of preterm birth or to safely administer antenatal corticosteroids, even when authorised to do so by health authorities.18, 19 Additionally, birth attendants might be unaware of antenatal corticosteroids as a treatment and health-care facilities might have poor or sporadic access to the necessary supplies.19
We aimed to assess the feasibility, effectiveness, and safety of a multifaceted intervention designed to increase the use of antenatal corticosteroids at all levels of health care. The intervention included components to improve identification of women at risk of preterm birth and to facilitate appropriate use of antenatal corticosteroids.20
Section snippets
Trial design and participants
The Antenatal Corticosteroids Trial (ACT) was an 18-month, two-arm, parallel, cluster-randomised trial done in geographical clusters at seven sites of the Global Network for Women's and Children's Health Research.20, 21 Clusters were distinct geographical rural and semi-urban settings in Argentina, Zambia, Guatemala, Belgaum (India), Nagpur (India), Pakistan, and Kenya, described elsewhere.21, 22 Clusters that had established an effective birth registry with at least 300 births annually in the
Results
The ACT trial took place between October, 2011, and March, 2014, with start dates varying by site. 102 clusters were eligible for the study—six in Argentina, ten in Zambia, ten in Guatemala, 20 in Belgaum, India, 20 in Nagpur, India, 20 in Pakistan, and 16 in Kenya. We randomly assigned 51 clusters to the intervention group and 51 to control. One Guatemalan cluster assigned to the control group withdrew because of unrest and staff concerns about safety (unrelated to the trial). Therefore, 51
Discussion
In this study, we assessed the health effects of a population-based multifaceted strategy to identify women at high risk of preterm birth and administer antenatal corticosteroids in low-resource settings. The intervention effectively increased the use of antenatal corticosteroids to 45% of women delivering infants less than the 5th percentile for birthweight, compared with about 10% in control clusters. However, we also identified overtreatment with antenatal corticosteroids in the intervention
References (36)
- et al.
Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis
Lancet
(2013) - et al.
Every Newborn: progress, priorities, and potential beyond survival
Lancet
(2014) - et al.
Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost?
Lancet
(2014) - et al.
Evidence-based, cost-effective interventions: how many newborn babies can we save?
Lancet
(2005) - et al.
Use of prenatal corticosteroids for preterm birth in three Latin American countries
Int J Gynaecol Obstet
(2010) - et al.
Who has been caring for the baby?
Lancet
(2014) - et al.
A conference report on prenatal corticosteroid use in low- and middle-income countries
Int J Gynaecol Obstet
(2011) - et al.
Extreme caution is needed before scale-up of antenatal corticosteroids to reduce preterm deaths in low-income settings
Lancet Glob Health
(2014) - et al.
Dating gestational age by last menstrual period, symphysis-fundal height, and ultrasound in urban Pakistan
Int J Gynaecol Obstet
(2010) - et al.
Every Newborn: health-systems bottlenecks and strategies to accelerate scale-up in countries
Lancet
(2014)
The Maternal and Newborn Health Registry study of the Global Network for Women's and Children's Health Research
Int J Gynecol Obstet
Neonatal sepsis and death after multiple courses of antenatal betamethasone therapy
Am J Obstet Gynecol
The effect of corticosteroids for fetal maturation on perinatal outcomes. Consensus Development Conference Statement
Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth
Int J Epidemiol
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Cochrane Database Syst Rev
The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essentials Medicines for Children)
Commissioners' report September 2012
Corticoesterides antenatales: empleo y actitud del personal medico ginecoobstetra
Ginecol Obstet Mex
Cited by (235)
Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks
2024, American Journal of Obstetrics and GynecologyA comparison of 2 doses of antenatal dexamethasone for the prevention of respiratory distress syndrome: an open-label, noninferiority, pragmatic randomized trial
2024, American Journal of Obstetrics and GynecologyThe top determinants and magnitude of preterm neonatal mortality in Ethiopia. Systematic review and meta-analysis
2023, Journal of Neonatal NursingUpdated WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes
2022, The Lancet Global HealthLow-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy
2022, American Journal of Obstetrics and GynecologyCitation Excerpt :A more recent study, again in low-resource jurisdictions, demonstrated the benefit of the use of Dex-P.14 A particular point of contrast between these 2 studies, and a potential explanation for the discordant findings, was the far higher quality and standardization of antenatal and neonatal care provided to most subjects in the latter study. Given this, more subtle adverse effects of ACS treatments, such as higher rate of maternal infection and hyperglycemia or fetal hypoglycemia and blunted adrenal function, may have a greater impact in low- and middle-income countries’ (LMICs) delivery settings with limited capacity to provide antenatal care and/or postpartum support to the mother and infant.12,13,15–19 Thus, optimizing the dosing for this very important therapy is one of the most pressing challenges that perinatal medicine is currently facing.
The complex challenge of antenatal steroid therapy nonresponsiveness
2022, American Journal of Obstetrics and Gynecology